U.S. life sciences company Illumina Inc on Tuesday defended its $7.1 billion acquisition of biotech firm Grail Inc , pledging to keep selling its DNA sequencing services to other firms, as it ...

Illumina announced Tuesday it plans to appeal the European Commission's decision to prohibit the company's acquisition of cancer detection company GRAIL.

Illumina Inc. was formally ordered to undo its $7 billion acquisition of cancer-test provider Grail Inc. as the European Union ramped up a legal fight over a deal the firms completed without its ...

Shares of genomics company Illumina (NASDAQ:ILMN) fell 6.3% in the afternoon session after China put the company on its "unreliable entity" list, opening the door to possible sanctions. The move ...

Illumina Inc.’s blocked $7 billion takeover of cancer-detection provider Grail Inc. should never have been probed by the European Union, according to a top court ruling that undermines the EU ...

Illumina Inc.’s was ordered to unwind its $7 billion acquisition of cancer startup Grail by the Federal Trade Commission, an uncommon move by antitrust regulators who said the deal raises ...

Illumina said Thursday it has won in the Federal Trade Commission's case challenging its $7.1 billion acquisition of cancer detection company GRAIL.

Biotech giant Illumina says it will undo its $7.1 billion purchase of the cancer-screening company Grail after losing legal battles with antitrust enforcers in the U.S. and Europe.

Illumina defends $7.1 bln Grail buy to fend off antitrust regulators Credit: REUTERS/Mike Blake December 13, 2022 — 04:50 pm EST Written by Diane Bartz for -> ...